ANIP (anipharmaceuticals.com) יחס שווי שוק לשווי בספרים

ANI Pharmaceuticals generates revenue through the production of affordable generics and the sale of high-cost Cortrophin Gel for the treatment of rare pathologies. This chart reflects the company's price action at 2.79. Business stability is supported by a streamlined distribution network through pharmacy channels, which optimizes treatment costs and ensures an uninterrupted supply of medications to the market.

This indicator compares the market value of ANI Pharmaceuticals (ANIP) to its net assets, determining the extent to which the business is overvalued or undervalued relative to its book value. By analyzing the trend of the market-to-book ratio, an investor can assess the company's resilience to pricing pressure in the generics segment and the risks of patent expiration, both of which directly impact the fundamental value of the assets.